Dr. Casulo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
601 Elmwood Ave
# Box
Rochester, NY 14642Phone+1 585-275-5863Fax+1 585-273-1051
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2012
- Yale-New Haven Medical CenterResidency, Internal Medicine, 2004 - 2008
- State University of New York Downstate Medical Center College of MedicineClass of 2004
Certifications & Licensure
- NY State Medical License 2008 - 2025
- CT State Medical License 2007 - 2008
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies Start of enrollment: 2012 Oct 01
- Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma Start of enrollment: 2013 May 01
- A Phase II Study of Doxycycline in Relapsed NHL Start of enrollment: 2014 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 260 citationsAxicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.Caron A Jacobson, Julio C Chavez, Alison R Sehgal, Basem M William, Javier Munoz
The Lancet. Oncology. 2022-01-01 - 7 citationsFollicular lymphoma: is there an optimal way to define risk?Carla Casulo
Hematology. American Society of Hematology. Education Program. 2021-12-10 - 26 citationsFollicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and earl...Farheen Mir, Federico Mattiello, Andrew Grigg, Michael Herold, Wolfgang Hiddemann
American Journal of Hematology. 2020-09-16
Journal Articles
- Venetoclax plus R- or G-CHOP in Non-Hodgkin Lymphoma: Results from the CAVALLI Phase 1b TrialAndrew D Zelenetz, Andre Goy, Mehrdad Mobasher, Carla Casulo, Blood
Abstracts/Posters
- Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)Carla Casulo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classi...Carla Casulo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin LymphomaCarla Casulo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- The effect of duvelisib, a dual inhibitor of PI3K-I on components of the tumor microenvironment in previously untreated follicular lymphoma.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Press Mentions
- POD24 Predicts Poor Prognosis in Follicular LymphomaDecember 1st, 2021
- Wilmot Hosts Deaf High School Students for Internship, Inspiring New Career PossibilitiesAugust 13th, 2021
- Finding Family and France, Figuratively: One Lymphoma Patient's Stem Cell Transplant StoryJune 3rd, 2021
- Join now to see all
Professional Memberships
- Member
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: